OptimizeRx Q3 revenue $15.1M, down 6% YoY; GAAP loss $0.19/share; FY guidance reaffirmed

OptimizeRx Corp

2022-Q3 EPS reported -$0.62 revenue$42,795,699

Revenue $15.1M (-6% YoY, +8% QoQ); gross margin improved to 62% from 56%.
GAAP net loss $3.5M ($0.19 per share); non-GAAP net income $1.3M ($0.07 per share).
Operating cash flow $7.9M in first nine months; cash & investments $78.8M.
FY2022 guidance reiterated: revenue $62M-$68M, gross margin 59%-62%.
Repurchased 1.1M shares YTD at average price of $16.70 per share.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.98

OptimizeRx Corp reported third quarter ended September 30, 2022 results: revenue $15.1 million, net income $3.5 million or $(0.19) per basic and diluted share, EPS $(0.19). Guidance reaffirmed.

Period: third quarter ended September 30, 2022
Revenue: $15.1 million
Net income: $3.5 million or $(0.19) per basic and diluted share
EPS: $(0.19)
Guidance: reaffirmed
Result: reported results

Exact text from the filing

OptimizeRx Reports Third Quarter 2022 Financial Results - Q3 Revenue of $15.1 million, down 6% year-over-year

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

OptimizeRx Corp filing history →

Source: SEC EDGAR

accession 0001213900-22-070127

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.